ATH net loss up 93% to A$23.4M; Phase 3 ATH434 on track
ATH reported net loss increased 93% to A$23.4M as R&D and admin costs rose, while its Phase 3 ATH434 trial is on track.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.